Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Trial Profile

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms POSEIDON
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 02 Aug 2019 Planned number of patients changed to 132.
    • 19 Dec 2018 According to an Aimmune Therapeutics media release, Brian Vickery, M.D., Associate Professor of Pediatrics at Emory University and Founding Director of the Food Allergy Center at Children's Healthcare of Atlanta, member of the Aimmune Scientific Advisory Board, is the Principal Investigator for the POSEIDON trial.
    • 17 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top